Member Info for Brand

Saw an email from Consilium today confirming that the recent job advert for a Senior Medical Writer was indeed a new role.

Xviolet - that page looks to updated pretty regularly

https://www.frontiersin.org/articles/10.3389/fimmu.2022.968991/full

Conclusions: We discovered circulating miRNAs associated with COVID-19 severity and mortality. The identified DE miRNAs provided clues on COVID-19 pathogenesis, highlighting signatures of impaired interferon and antiviral responses, inflammation, organ damage and cardiovascular failure as associated with severe disease and death.

Genuinely LOL-ing over here

Does anyone know when recovery is meant to report on pax?

This seems pretty good you guys

"In conclusion, even closely related SARS-CoV-2 (sub)variants can differ in their biology, as indicated by different BA.1 and BA.2 replication kinetics, and in their response to antiviral treatments, as indicated by differences in the virus responses to betaferon, EIDD-1931/ molnupiravir, and aprotinin and differing levels of synergism of betaferon combinations with other antiviral drugs. Betaferon combinations with nirmatrelvir and, in particular, with EIDD-1931 and aprotinin displayed high levels of synergism, which makes them strong candidates for clinical testing."

https://www.journalofinfection.com/article/S0163-4453(22)00455-8/fulltext#%20

I am curious if the move from poly to go over 25% (and then to 27ish - which keeps them over 25% after all those share options for the board) was strategic in the sense that if they were to sell out to a single Investor, said investor could then demand a seat on the board.

Just connecting dots, would be interested in others views.

Anything that brings inf vs covid to the world's attention is good for the company at this point. The market is absolutely massive and SNG001 well and truly novel with a much broader patient range.

Tbh I am just happy someone's used the term bottom drawer and not bottom draw!

Imho not much has changed since the AGM. Feedback from those that attended (across multiple boards) was positive and optimistic. The company are hiring a senior medical writer, which again looks to be a positive and the board have all given themselves huge share options.

Potential news:
PASC data from sprinter or potentially from combined trials
ACTIV 2 top line results
First patient dosed on a platform trial(s)
Awarding of grants

Anyone got anything else to add?

Re SNG001 treating PASC as opposed to preventing it.

There have been papers hypothesizing that PASC could be "remnants" of the virus continuing to affect the patient well after the initial infection.

The theory is that by treating w an potent antiviral, those remnants would be cleared from the body. It seems there are different 'types' of PASC and it could well be that SNG001 is appropriate for some patients and not for others.

This is though, just a theory at this point. A trial is necessary and indeed justified.

https://local.nihr.ac.uk/case-studies/covid-19-research-in-primary-care/30260

"All the patients that we recruited to the study have since been re-consented as the Synairgen research team wanted to extend the study to examine the impact of long COVID-19 on patients. "

Just to add to the senior writer topic - if the company didn't want all of those details in the public domain it would have been just as easy to work through a recruiter and keep their name off the advert.

Thank you for sharing this Tommy. It would seem this finding opens up a "sweet spot" for application of SNG001 as part of SOC, after admission and before steroids.

Penny for anyone thoughts on why the mortality is so much worse in the 90 day cohort Vs the 35 day group.

Well noted Bryosa - I see everything through a PR tinted lens!

Feels like there are a few people on this board that could do that role!

(In all seriousness tho, absolutely brilliant to see - expect this role would be reporting in to Brooke and the marketing team - you don't market something you don't expect to sell!)

Excellent finds Tommy - thank you for your relentless pursuit of data and indeed for sharing here.

Although like anyone that's held sng for a good while I am frustrated we haven't seen the PASC data from sprinter/Activ/earlier trials yet - to see the science stacking up like this is incredibly exciting.

You know it's good info when the same old tired accounts turn it in to petty arguement

At the risk of stating the obvious - it's pretty awesome that after all the presentations, posters and seminars etc at the largest gathering of respiratory health professionals for over 2 years, the lead story is SNG001.

Prime Time SNG

https://twitter.com/MidwestHedgie/status/1545045885758763009?t=zLkRhRm8beSjxVXv6yGfcQ&s=19